Emcure Pharmaceuticals Limited CC-Nov25.pdf · 2025-11-11
Yes, thank you for taking my question. Congrats on a good set of numbers. My question is when we look at the last 3 to 4 quarters, we have done very well in terms of penetrating into the chronic space, cardio diabetes, whether it is through acquisition or in-licensing. If I look at probably the way things are moving forward with the tie -up with Novo Nordisk, this seems to be ga thering well. So some color with respect to how do we see the chronic portion of the business improving from here and also on the newer therapies? The second part of the question is partly you answered about the MR activity earlier that we are one of the very few companies who have built a fair amount of manufacturing capabilities as well. So as these manufacturing capabilities comes into the fore in terms of complex launches globally, I'm looking about more of longer term, how do we see the business movin g towards, say, 25% and where do you see the coverage?
Sure, sir. Do you have any target in mind with respect to how much of chronic are we targeting, say, in two, three years and how much margin we would be looking at?